Other languages CRISPR Therapeutics AG

Equities

CRSP

CH0334081137

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-08 pm EDT			5-day change	1st Jan Change
53.23 ^USD	+0.24%		-1.33%	-14.97%

Jun. 11	Transcript : CRISPR Therapeutics AG Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 09:20 AM
May. 23	CRISPR Therapeutics Names Naimish Patel as Chief Medical Officer; Promotes Julianne Bruno to Chief Operating Officer	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

CRISPR Therapeutics Names Naimish Patel as Chief Medical Officer; Promotes Julianne Bruno to Chief Operating Officer	May. 23
CRISPR Therapeutics Announces Executive Changes	May. 23
CRISPR Therapeutics AG Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08
CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing in Vivo Gene Editing Approach	May. 08
Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing	Apr. 17
CRISPR Therapeutics Swings to Q4 Profit, Revenue Increases	Feb. 21
CRISPR Therapeutics AG Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 21
CRISPR Therapeutics AG Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 21
Crispr Therapeutics Ag Insider Sold Shares Worth $1,607,177, According to a Recent SEC Filing	Feb. 16
CRISPR Therapeutics to Sell About $280 Million of Common Shares	Feb. 13
Crispr Therapeutics Announces European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY?	Feb. 13
CRISPR Therapeutics Gets FDA Approval For Casgevy to Treat Transfusion-Dependent Beta Thalassemia	Jan. 16
CRISPR Therapeutics Announces U.S. Food and Drug Administration Approval of CASGEVY? for the Treatment of Transfusion-Dependent Beta Thalassemia	Jan. 16
US FDA approves Vertex/CRISPR gene therapy for an inherited blood disorder	Jan. 16
US FDA approvals bounce back in 2023, sparking hopes of a biotech recovery	Jan. 02
CRISPR Therapeutics Chief Medical Officer Phuong Khanh Morrow Resigns	Dec. 20
CRISPR Therapeutics AG Announces Resignation of Phuong Khanh Morrow as Chief Medical Officer, Effective January 26, 2024	Dec. 19
CRISPR Therapeutics AG Adopts Positive Opinion for the Conditional Approval of Casgevy	Dec. 15
Bluebird signs pact with insurer for sickle cell gene therapy	Dec. 14
CRISPR Therapeutics AG, CRISPR Therapeutics Limited, TRACR Hematology Ltd Enters into an Amendment to the Amended and Restated Joint Development and Commercialization Agreement with Vertex Pharmaceuticals ( Europe) Limited	Dec. 13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages CRISPR Therapeutics AG

Equities

CRSP

CH0334081137

Other languages

Filters